Towards Healthcare

Medical Cannabis Market Size and its Uses in Compounds

The global medical cannabis market valued at USD 14.34 billion in 2024, is anticipated to reach USD 52.23 billion by 2034, growing at a CAGR of 13.8% over the next decade. Chronic pain management led in 2022, holding 52% of the share. North America dominates with a 56% share, driven by early legalization, a strong market presence and increasing popularity.

Insight Code: 5099 Format: PDF / PPT / Excel
Last Updated: 27 March 2025 Category: Therapeutic Area

Principal Consultant

Rohan Patil

Reviewed By

Aditi Shivarkar

Medical Cannabis Market and its Impact on Neurological Condition

The medical cannabis market is anticipated to grow from USD 16.32 billion in 2025 to USD 52.23 billion by 2034, with a compound annual growth rate (CAGR) of 13.8% during the forecast period from 2025 to 2034. The rising prevalence of chronic pain, growing research and development, and growing awareness drive the market.

Medical Cannabis Market Size 2023 - 2034

Medical Cannabis Market Report Highlights

  • North America dominated the global medical cannabis market in 2024.
  • Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
  • By product type, the dissolvable/powder segment held a dominant presence in the market in 2024.
  • By product type, the oil segment is predicted to witness significant growth in the market over the forecast period.
  • By derivative, the cannabidiol segment held the largest share of the medical cannabis market in 2024.
  • By derivative, the tetrahydrocannabinol segment is expected to grow at the fastest rate in the market during the forecast period.
  • By route of administration, the inhalation segment held a major share of the market in 2024.
  • By route of administration, the oral segment is anticipated to grow with the highest CAGR in the market during the studied years.
  • By application, the pain management segment registered its dominance in the market in 2024.
  • By application, the neurological health management segment is projected to expand rapidly in the market in the coming years.
  • By distribution channel, the hospital pharmacy segment led the global medical cannabis market in 2024.
  • By distribution channel, the online pharmacy segment is estimated to show the fastest growth over the forecast period.

Medical Cannabis Market Overview

In 2023, according to the World Health Organization, it is estimated that around 50 million individuals are suffering from Epilepsy and showing a greater risk of premature death due to epilepsy. Medical cannabis hits high notes for Epilepsy, Chronic Pain Management and Rare Diseases.

Medical cannabis is obtained from the Cannabis Sativa plant and has been used for centuries due to its potential therapeutic benefits. Cannabis contains two main active compounds: Tetrahydrocannabinol (THC) and Cannabidiol (CBD). THC is known for its psychoactive properties, whereas CBD is non-psychoactive and has a variety of health benefits. The human body contains an endocannabinoid system (ECS), which regulates various physiological processes. Cannabinoids found in medical cannabis interact with receptors in the ECS, influencing processes such as pain perception, immunity and mood. One of the primary applications of medical cannabis is pain relief and it is used for various symptoms and diseases. THC can help alleviate chronic pain by altering how pain signals are processed in the brain. CBD, on the other hand, may have anti-inflammatory and analgesic properties without causing the "high" associated with THC. Medical cannabis is also utilized to manage nausea and vomiting, often in patients undergoing chemotherapy. THC can help reduce these symptoms and improve the quality of life for individuals undergoing cancer treatments.

In some cases, medical cannabis is prescribed for muscle spasms and spasticity associated with conditions like multiple sclerosis. The cannabinoids' muscle-relaxant properties may provide relief for these symptoms. It's crucial to highlight that the legal status of medical cannabis varies widely around the world and even within different regions of a country. Some places have legalized its use for medicinal purposes, while others still have strict regulations or complete prohibition. Before considering medical cannabis, individuals should consult with healthcare professionals to discuss potential benefits, risks and legal implications based on their specific health conditions and local regulations.

  • In January 2025, Avicanna, Inc. announced a strategic collaboration with Vectura Fertin Pharma to improve the understanding of medical cannabis access and applications in Canada. Vectura Fertin Pharma is a subsidiary of Philip Morris International (PMI) that specializes in cannabinoid-based medicines and has a clinical R&D department that has led to the commercialization of more than 30 products.
  • In December 2024, a South Carolina senator introduced a bill as part of the “South Carolina Compassionate Care Act” legislation to legalize the medical use of cannabis for patients with certain qualifying medical conditions. Medical marijuana is being legalized to be used for specified debilitating medical conditions for which opioids are the standard course of treatment.
  • In June 2024, Organigram Holdings, Inc. announced an investment of €14 million in Sanity Group, a leader in the German cannabis market. Sanity Group holds approximately 10% share of the German medical cannabis market with a robust distribution network of over 2,000 pharmacies working with over 5,000 physicians. The investment was also made to expand the supply agreement.

Impact of AI on the Medical Cannabis Market

To gain a competitive advantage in the production of premium medical cannabis, growers are looking to artificial intelligence. A new degree of understanding and control is available to farmers thanks to AI algorithms. In order to forecast the ideal circumstances for plant health and productivity, these intelligent systems are able to evaluate an infinite number of data points in real time. In addition to improving the medical cannabis's quality, this also makes it more consistent, which is important for uses in medicine where exact dosage and consistent results are crucial. Artificial intelligence (AI) helps decrease waste and lessen the environmental impact of cannabis growth by determining the best growing conditions.

The Role of Medical Cannabis in Treating Various Symptoms and Conditions

In states where medical marijuana is sanctioned, its approval extends to a diverse range of medical conditions, such as

  • Severe and Persistent Pain
  • Multiple Sclerosis
  • Chemotherapy-Induced Nausea
  • Epilepsy
  • Alzheimer's
  • ALS
  • HIV/AIDS
  • Crohn's Disease
  • Glaucoma
  • Migraines
  • Anorexia
  • Wasting Syndrome
  • Irritable Bowel Syndrome
  • Post-Traumatic Stress Disorder

It's imperative to recognize that some endorsed applications lack robust scientific validation. This discrepancy arises, in part, from the challenge researchers face in conducting comprehensive studies on a substance that, despite state-level approval, remains federally prohibited. The intricacies of this legal landscape contribute to limitations in establishing conclusive evidence for certain medicinal uses of Cannabis. More and more folks are realizing the amazing health benefits of medical cannabis, and it's causing a big demand boost in the market. People are getting hip to the therapeutic perks of cannabis-based products and as we all get more comfortable with using cannabis for medical reasons, the demand is shooting up. Ongoing research backing up its effectiveness also plays a role, making these products even more popular. It's like everyone's realizing that cannabis is a legitimate and valuable part of taking care of our health.

Active Medical Cannabis Cardholders

A cannabis patient cardholder is someone whose state's regulatory body has issued a medical marijuana card or license. This card verifies that the holder has a qualifying medical condition that makes them eligible to use cannabis for therapeutic purposes.

Prescription Drugs Based on Cannabis Compounds

The FDA hasn't endorsed marijuana for health issues, but it has given the thumbs up to two prescription medications featuring synthetic cannabinoids.

FDA-Approved Medical Cannabis Drugs:

  • Dronabinol, also known as Marinol, comes into play for managing chemotherapy-induced nausea and vomiting and addressing appetite and weight loss in individuals with HIV/AIDS.
  • Nabilone, marketed as Cesamet, steps in to alleviate nausea and vomiting from chemotherapy when other remedies fall short.

What sets these drugs apart from medical marijuana is the ability to regulate the active ingredient precisely, ensuring a consistent and known dosage each time. This level of control contributes to a more reliable and predictable therapeutic experience.

Cannabis has Potential Benefits in Managing Epilepsy

Epilepsy is a persistent neurological condition affecting individuals across all age groups. Globally, approximately 50 million people grapple with epilepsy, marking it as one of the most prevalent neurological disorders. Alarmingly, around 80% of those affected reside in low and middle income nations. With proper diagnosis and treatment, up to 70% of individuals living with epilepsy could potentially lead seizure-free lives. Unfortunately, the risk of premature death is three times higher in people with epilepsy compared to the general population. Regrettably, a significant number of individuals in low-income countries, around three-quarters, lack access to the necessary treatment. Beyond the medical challenges, many regions worldwide witness people with epilepsy and their families enduring the burden of societal stigma and discrimination. Addressing these issues requires a concerted effort to enhance accessibility to proper care and eliminate misconceptions surrounding epilepsy. Research suggests that certain compounds in cannabis, such as Cannabidiol (CBD), may have anticonvulsant properties and could potentially help manage epilepsy. CBD interacts with the endocannabinoid system in the body, influencing neural activity. However, it’s crucial to consult with a healthcare professional before considering any cannabis-related treatment for epilepsy, as the effectiveness and safety can vary and individual responses may differ.

Global Impact of Epilepsy: Greater Risk Found in Neonatal

While some studies suggest that certain compounds in cannabis, particularly cannabidiol (CBD), may have anticonvulsant properties, the overall evidence supporting cannabis as a primary treatment for epilepsy is not yet conclusive.

For Instance,

  • Epidiolex, a CBD-based medication, has been approved by the U.S. Food and Drug Administration (FDA) for specific types of seizures associated with epilepsy. Cannabis is gaining recognition for its role in epilepsy treatment, with an increasing demand for its medicinal use.
  • In 2023, according to the World Health Organization, around 50 million individuals in the United States are affected by epilepsy, comprising 3 million adults and 470,000 children. Notably, epilepsy stands out as one of the leading causes of hospital inpatient stays among children aged 0 to 17 in the U.S.

Many individuals are finding relief through cannabis-based therapies, and as awareness grows, so does the demand for these medicinal products. This positive shift reflects a changing perspective on the potential benefits of cannabis in managing epilepsy, providing hope for those seeking alternative, effective treatments and increasing demand for medical cannabis in the market.

The challenge of legal and regulatory issues in the medical cannabis market is like facing a tricky obstacle course. Imagine each country having its own set of rules – some straightforward, others complex. The first hurdle is the patchwork of regulations globally; what's legal in one place might be strictly prohibited in another. The clash of rules between regions adds complexity, creating a regulatory puzzle. It's like trying to follow a map with conflicting instructions, making the journey more challenging. Concerns about misuse and safety act as barriers. Some fear that opening the doors to medical cannabis could lead to problems. This concern adds an extra layer of difficulty, making the regulatory landscape akin to a tricky obstacle course that needs careful navigation.

Additionally, varying legal statuses across jurisdictions create complexities for companies operating in multiple markets. Despite its growing acceptance, navigating the evolving regulatory landscape remains a key factor influencing the expansion of the medical cannabis industry.

Segmental Insights

Dissolvable/Powders Segment Dominated

By product type, the dissolvable/powder segment held a dominant presence in the medical cannabis market in 2024. Powdered cannabis is most widely preferred as it can be dissolved in a suitable solvent and administered easily through the oral route. It results in rapid absorption and distribution throughout the body. The maintenance of an appropriate dose is also possible through powders. Technological advancements lead to the latest innovations, such as nanoemulsion technology to quickly dissolve powdered cannabis.

Oil Segment: Significantly Growing

By product type, the oil segment is predicted to witness significant growth in the medical cannabis market over the forecast period. Cannabis oil is derived from the cannabis plant and is the most concentrated form of cannabis. It is widely used to get relief from pain, anxiety, depression, and sleep disorders. Oils are used as part of traditional medicines to support human health and well-being. Ongoing research efforts are made to find novel procedures for extracting cannabis oil in higher quantities.

Cannabidiol Segment Held the Largest Share

By derivative, the cannabidiol segment held the largest share of the medical cannabis market in 2024. Cannabidiol is one of the 85 active cannabinoids within the cannabis plant. It constitutes a major percentage of all the ingredients, accounting for 40% of the plant extract. It is used for treating various chronic conditions, including seizures, chronic pain, and muscle spasms affecting the brain and spinal cord. The U.S. FDA has approved cannabidiol for treating Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex, potentiating its demand for extended applications.

Tetrahydrocannabinol Segment: Fastest-Growing

By derivative, the tetrahydrocannabinol segment is expected to grow at the fastest rate in the market during the forecast period. Tetrahydrocannabinol (THC) is predominantly found in the leaves and flowers of the cannabis plant. It is used to treat multiple sclerosis, nerve pain, and chemotherapy-induced nausea and vomiting. It also stimulates the appetite. It is available in different forms, such as smokable products, oils & tinctures, and edibles.

Inhalation Segment Held a Major Share

By route of administration, the inhalation segment held a major share of the medical cannabis market in 2024. Inhalation is the most preferred route of administration as it is directly passed into the bloodstream through the lungs and subsequently into the brain. Inhaled cannabis provides a rapid onset of action and reduced systemic side effects. A precise amount of dose is delivered to the lungs, avoiding unnecessary overdosing. Cannabis is inhaled by many hospitalized patients or unconscious people who are unable to take cannabis through the oral route.

Oral Segment: Fastest-Growing

By route of administration, the oral segment is anticipated to grow with the highest CAGR in the market during the studied years. Cannabis is administered through the oral route to increase medication adherence for all age groups. It is easy to administer and cost-effective, eliminating the need for skilled personnel or a specified device to ingest cannabis. It can eliminate the chances of breathing problems and the need for smoking. The oral route is preferred for treating nausea, loss of appetite, neuropathic pain spasticity, epilepsy, etc.

Pain Management Segment Dominated

By application, the pain management segment registered its dominance in the medical cannabis market in 2024. The rising prevalence of chronic pain due to severe disorders such as cancer, neuropathy, and inflammation boosts the segment’s growth. It is estimated that neuropathic pain affects around 7% to 8% of the total population globally and increases to around 20% to 30% in people with diabetes. A 2023 comparative study between cannabis and opioids published in the Journal of Cannabis Research proved that cannabis can positively affect pain-related factors such as emotion and mood, functionality, and overall sense of well-being, in addition to reducing pain intensity.

Neurological Health Management Segment: Fastest-Growing

By application, the neurological health management segment is projected to expand rapidly in the market in the coming years. Cannabis has immense potential in treating neurological diseases, such as neuropathic pain, migraine, multiple sclerosis, Parkinson’s disease, Huntington’s disease, and motor neuron disease. The increasing prevalence of these disorders potentiate the demand for cannabis as a therapeutic. A recent study published in the Journal of Parkinson’s on 367 people suffering from Parkinson’s disease found that 13% of the people use cannabis for treating their disorder.

Hospital Pharmacy Segment Led in 2024

By distribution channel, the hospital pharmacy segment led the global medical cannabis market in 2024. The segmental growth is attributed to the presence of skilled professionals, favorable infrastructure, and suitable capital investments. Pharmacists stay updated with the changing regulatory policies regarding extended applications of cannabis. Hospitals follow stringent regulatory guidelines and distribute cannabis within these guidelines. Hospital pharmacists also assist in managing the potential adverse effects of cannabis in patients.

Online Pharmacy Segment: Fastest-Growing

By distribution channel, the online pharmacy segment is estimated to show the fastest growth over the forecast period. The rising adoption of smartphones and the rapidly expanding e-commerce sector augment the segment’s growth. Online pharmacy enables patients to order medical cannabis in the comfort of their homes. It also provides online consultation services and 24/7 facilities, attracting more customers. The increasing geriatric population also contributes to the segment’s growth.

Geographical Landscape

In North America, the geographical landscape for the medical cannabis market has seen significant changes in recent years. Canada has a well-established legal framework for both medical and recreational cannabis, allowing for cultivation, distribution and use. Several U.S. states, including California, Colorado and Florida, have developed robust medical cannabis markets. Mexico has also undergone legislative changes, decriminalizing cannabis for personal use and exploring avenues for medical cannabis legalization. The North American medical cannabis market exhibits a patchwork of regulations, with ongoing developments and shifting attitudes contributing to a dynamic landscape. As more regions and states embrace medical cannabis, the market is likely to continue evolving across the continent.

In the Asia Pacific, the geographical landscape for the medical cannabis market is marked by a mix of regulatory approaches. While many countries maintain strict regulations or even criminalize cannabis, some are exploring or implementing changes. Australia has made strides in medical cannabis legalization, establishing a framework for cultivation and distribution. In contrast, countries like Thailand and South Korea have taken steps toward cannabis decriminalization for medical purposes. However, the overall landscape in Asia Pacific remains diverse, with varying levels of acceptance and regulatory frameworks.

Latest Announcement by Industry Leaders

Barsha Man Pun, Finance Minister of the Government of Nepal, announced the legal cultivation and consumption of marijuana for medicinal purposes. He said that necessary laws would be framed for the commercial production of marijuana in the country. He allocated a budget of Rs 1.860 trillion for the fiscal year 2024-25.

The Fast-Evolving Landscape of Medical Cannabis

  • In January 2023, Celadon Pharmaceuticals Pic shared the exciting news that the UK Medicines and Healthcare Products Regulatory Agency (MRHA) has officially registered its cannabis active pharmaceutical ingredient at its Midlands facility, UK, ensuring compliance with Good Manufacturing Practices (GMP).
  • In February 2023, Aurora Cannabis Inc. joined forces with MedReleaf Australia, introducing an innovative medical cannabis brand called CraftPlant to the Australian market. CraftPlant brings three new products – Greendale, Navana and HiVolt – all derived from carefully cultivated strains, boasting THC dominance and enriched with high terpene content. This collaboration aims to provide doctors in Australia with various prescription options for their patients.
  • In June 2023, Avicanna Inc., a pioneer in cannabinoid-based pharmaceuticals, partnered with the Canadian Consortium for the Investigation of Cannabinoids. Together, they developed an educational course customized for the medical community in Canada, fostering a deeper understanding of cannabinoids.
  • In August 2023, Avicanna Inc. expanded its footprint by acquiring Medical Cannabis by Shopper's Business from Shoppers Drug Mart. To add to the celebration, they proudly launched MyMedi.ca, an innovative medical cannabis care platform, offering a comprehensive and user-friendly experience for individuals seeking medical cannabis solutions.

Medical Cannabis Market Strategic Companies

Medical Cannabis Market Companies

Medical Cannabis Market Segments

By Product Type

  • Dissolvable/Powders
  • Oil
  • Solids
  • Ointments & Creams

By Derivative

  • Cannabidiol
  • Tetrahydrocannabinol

By Route of Administration

  • Inhalation
  • Oral
  • Topical

By Application

  • Pain Management
  • Neuropathic Pain
  • Cancer
  • Inflammatory Pain
  • Neurological Health Management
  • Mental Health Management

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait

Meet the Team

Rohan Patil is a market research expert with 5+ years of experience in healthcare, specializing in market dynamics, emerging trends, and technology-driven innovations to guide data-driven decisions for healthcare organizations.

Learn more about Rohan Patil

Aditi Shivarkar, with 14+ years of healthcare market research experience, ensures the accuracy, clarity, and relevance of reports. Her expertise helps businesses make informed decisions and stay competitive in healthcare sectors.

Learn more about Aditi Shivarkar

Related Reports

Medical Cannabis Market Size Soars 13.8% of CAGR by 2034
FAQ's

Cannabis dispensaries across the country sell products derived from a variety of cannabis strains. While users frequently report varying effects on their symptoms from different strains, research in this area is limited.

Medical cannabis is legal in 38 states. More than two-thirds of US states and the District of Columbia have legalized Medical cannabis in various forms for medical purposes. More bills that would do the same thing are being considered. Some of those states also allow adults to use cannabis recreationally. Medical cannabis laws vary by state, with some prohibiting smoked forms or limiting THC doses.

Medical cannabis can be used to relieve pain. This includes a variety of chronic pain conditions, such as nerve damage, prevent nausea and vomiting, increase appetite.

World Health Organization, Food and Drug Administration, National Institute of Health, Department of Cannabis Control, MedlinePlus.gov, NYC.gov., GOV.UK.